



JC14 Rec'd PCT/PTO 06 MAY 2002

PCT  
H3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : SPYROS TSAKAS  
Serial No.: 10/089,486  
Filed : March 27, 2002  
For : CRYOPRESERVED AMNIOTIC HUMAN  
CELLS FOR FUTURE THERAPEUTIC,  
DIAGNOSTIC, GENETIC AND OTHER  
USES

Docket No.: 02-314

Examiner :

Art Unit :

RECEIVED

NOV 01 2002

TECH CENTER 1600/2900

900 Chapel Street  
Suite 1201  
New Haven, CT 06510-2802

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents and Trademarks  
United States Patent & Trademark Office  
Washington, D.C. 20231

Dear Sir:


In compliance with Applicant's duty of disclosure, the following documents are brought to the Examiner's attention:

"A Cryopreservative Procedure for Storing Cultivated and Uncultivated Amniotic Fluid Cells in Liquid Nitrogen", by S. Pentz et al., Journal of Medical Genetics, vol. 17, 1980, pp. 472-475;

"Transport and Storage of Amniotic Fluid Samples for Prenatal Diagnosis of Metabolic Diseases", by M.F. Niermeijer et al., Humangenetik, vol. 20, no. 2, 1973, pp. 175-178;

"Graft of Cryopreserved Human Amniotic Epithelial Cells in a Subject with Type B Niemann-Pick Disease", by B. Scaggiante et al., Pediatria Medica E. Chirurgia, vol. 9,






arabinogalactan is provided in the cryopreservation medium, optionally in combination with a second cryopreservation agent, such as dimethyl sulfoxide. The medium can be used for the cryopreservation of a wide variety of different cell types from different sources. For example, mammalian cells, including porcine, canine, human, equine, rodent and bovine cells can be cryopreserved in the medium. The presence of arabinogalactan in the medium protects the viability of cells in the medium during the process of freezing, storage and thawing.

U.S. Patent No. 5,879,937 to Roncarolo relates to improved methods of prenatal diagnosis that can be performed either in pregnancy, and/or with greater safety, and/or rapidity, and/or with greater accuracy than conventional methods. A volume of amniotic fluid containing fetal cells is extracted from a pregnant woman, and the fetal T-cells are propagated in a culture medium comprising one or more cytokines. The fetal T-cells are then diagnosed for genetic defects.

The Sackier et al. patent document relates to the application of amniotic cells, in particular, viable epithelial cells, to clinical procedures including the treatment of diseased or damaged tissues, e.g. in joints denuded of cartilage and vascular grafts. The invention also provides prosthetic devices which incorporate amniotic cells, and compositions for cosmetic use based upon amniotic cells or cell extracts. A further development uses amniotic



cells in the form of a semipermeable membrane, or coated onto, for example, microspheres; these structures act as filtration devices for the removal of toxic materials from, for example, blood or urine.

The Sakuragawa patent document relates to cells used for treating dementia. The cells for treating dementia comprises human amniotic epithelial cells. By transplanting the cells for treating dementia into the brain, since the transplanted cells produce chlorine acetyltransferase, the dementia such as Alzheimer's disease is cured or lightened.


The Kind et al. article relates to reprogramming human somatic nuclei by transfer into oocytes.

The Hu patent document is directed to human amniotic epithelial cells derived from placenta at delivery, and the methods for isolating, culturing, and cryopreserving them for future therapeutic uses. Additionally, the invention is directed to methods for inducing differentiation of these multipotentials cells, for assaying the cell types derived, and for manipulating the cells by gene transfection and other means for therapeutic applications, including but not limited to enzyme replacement and gene therapy, tissue regeneration and replacement, as well as burn and wound dressings.

Copies of the above documents and a listing on Form PTO-1449 are enclosed herewith.

None of the patent documents are believed to negate the patentability of the present invention.

RECEIVED  
NOV 01 2002  
TECH CENTER 1600/2900




No fee is believed to be due as a result of this Information Disclosure Statement. Should the Commissioner determine that a fee is due, he is hereby authorized to charge said fee to Deposit Account No. 02-0184.

Respectfully submitted,

SPYROS TSAKAS

By


  
Barry L. Kelmachter  
Attorney for Applicant

Area Code: 203  
Telephone: 777-6628 - ext. 114  
Telefax : 865-0297

Date: April 23, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231

on April 23, 2002  
(Date of Deposit)  
Nicole Motzer

Name and Reg. No. of Attorney  
  
Signature  
April 23, 2002  
Date of Signature

RECEIVED

NOV 01 2002

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete If Known**

Application Number	10/089,486
Filing Date	March 27, 2002
First Named Inventor	TSAKAS
Group Art Unit	
Examiner Name	
Attorney Docket Number	02-314

*(use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

[illegible]

RECEIVED

NOV 01 2002

TECH CENTER 600/2900

[illegible]

Date Considered

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	10/089,486
Filing Date	March 27, 2002
First Named Inventor	TSAKAS
Group Art Unit	
Examiner Name	
Attorney Docket Number	02-314

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	/	"A Cryopreservative Procedure for Storing Cultivated and Uncultivated Amniotic Fluid Cells in Liquid Nitrogen", by PENTZ ET AL., Journal of Medical Genetics, vol. 17, 1980, pp. 472-475	
	/	"Transport and Storage of Amniotic Fluid Samples for Prenatal Diagnosis of Metabolic Diseases", by NIERMEIJER ET AL., Humangenetik, vol. 20, no. 2, 1973, pp. 175-178	
	/	"Graft of Cryopreserved Human Amniotic Epithelial Cells in a Subject with Type B Niemann-Pick Disease", by SCAGGIANTE ET AL., Pediatria Medica E. Chirurgia, vol. 9, no. 1, January 1987 - February 1987, pp. 89-92	
	/	"Therapeutic Cloning: Needs and Prospects", by KIND ET AL., Seminars in Cell & Development Biology, vol. 17, no. 3, June 1999, pp. 1171-1174	

RECEIVED

NOV 01 2002

TECH CENTER 1600/2900

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.